Regulatory & Political Developments

The FDA is preparing for a highly anticipated Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026, which will evaluate whether seven peptides—including BPC-157, TB-500, KPV, and MOTS-c—should be added to the Section 503A Bulk Drug Substances List. However, newly released FDA staff briefing documents indicate the agency’s internal reviewers are recommending against their approval, citing limited evidence of safety and efficacy. For example, staff noted a complete lack of human studies for TB-500.

The upcoming meeting is already generating political and industry friction. The Partnership for Safe Medicines (PSM) formally submitted comments on July 10 strongly opposing the addition of these peptides due to the absence of adequate clinical trials. Meanwhile, the makeup of the PCAC panel itself is drawing public criticism for alleged conflicts of interest, as some newly appointed members reportedly possess financial ties to wellness clinics and compounding pharmacies.

### Legal & Enforcement Actions

Federal regulators are tightening the leash on the online distribution of both peptides and compounded weight-loss drugs. Over the past week, the FDA issued approximately 25 to 30 warning letters to telehealth companies for false or misleading advertising related to compounded GLP-1 medications (such as semaglutide and tirzepatide). According to FDA Commissioner Marty Makary, the agency is paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms.

On the "research use only" (RUO) front, a recent CBS News investigation exposed New York City bodegas openly selling unregulated peptides—including the experimental drug retatrutide—over the counter to individuals without age verification or prescriptions. The vials reportedly lacked RUO disclaimers on the physical labels, and the associated Certificates of Analysis (COAs) were confirmed by a third-party laboratory to be falsified.

In addition, civil liability and regulatory scrutiny regarding compounding standards are escalating. Legal experts note that plaintiff attorneys and state pharmacy boards are increasingly citing USP Chapters 795 and 797 as rigid baselines in compounding litigation, punishing facilities with thin documentation.

### Market Watch

The escalating regulatory climate is causing ripples in the financial sector. According to a recent industry report, major payment processors and banks are increasingly categorizing peptide sales alongside high-risk merchant classes (like CBD and offshore supplements). Legacy underwriting systems are struggling to distinguish between compliant RUO operators and illicit retail actors, potentially leading to payment processing hurdles for legitimate businesses. On the equities side, telehealth platform Hims & Hers saw its stock dip in response to the FDA's broader telehealth warning sweep, reflecting heightened investor sensitivity to compliance actions.

### Compliance Takeaway for RP Wellness

The FDA’s crackdown on misleading telehealth claims and mainstream media exposure of bodegas selling RUO chemicals highlight an aggressive enforcement environment. For a research-peptide supplier, strict adherence to B2B research-only channels is paramount. RP Wellness must rigorously verify that all Certificates of Analysis (COAs) are authentic, ensure that "Research Use Only" labeling is prominently displayed directly on all physical vials (not just the website), and continuously monitor merchant-processing relationships as banking risk standards tighten.